from my humble understanding of what has transpire
Post# of 36537
the numbers for Veneto were exaggerated and/or inflated by Veneto excecutives.....for a private company...that's routine....Generex worked with the numbers that they were given....along with an independent auditor.....but kept a "what if" clause, after the 1st quarter of operations, to renegotiate if needs be....pretty smart i would say....exactly what they expected....numbers did not add up.....
previous deal 35 million $, up front cash needed at 30 % or more for otc comp....dilution to the max...
renegotiated deal 21 million $ in shares and close the deal....no further dilution..
yeah provided Generex was conflicted in the first deal, they got the upper hand in the 2nd deal.....and can get out of the limited price protections for the shares if more negative issues/numbers were to be found....